- Previous Close
1.1900 - Open
1.2500 - Bid 1.2000 x 200
- Ask 1.2500 x 200
- Day's Range
1.2204 - 1.2500 - 52 Week Range
1.0900 - 3.2560 - Volume
25,318 - Avg. Volume
683,487 - Market Cap (intraday)
312.426M - Beta (5Y Monthly) -0.54
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.67
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
lyell.comRecent News: LYEL
View MorePerformance Overview: LYEL
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LYEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LYEL
View MoreValuation Measures
Market Cap
304.64M
Enterprise Value
-133.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.59k
Price/Book (mrq)
0.54
Enterprise Value/Revenue
1.94k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.84%
Return on Equity (ttm)
-32.26%
Revenue (ttm)
54k
Net Income Avi to Common (ttm)
-210.26M
Diluted EPS (ttm)
-0.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
491.12M
Total Debt/Equity (mrq)
10.63%
Levered Free Cash Flow (ttm)
-87.02M
Research Analysis: LYEL
View MoreCompany Insights: LYEL
LYEL does not have Company Insights